Compare · ALUR vs SYK
ALUR vs SYK
Side-by-side comparison of Allurion Technologies Inc. (ALUR) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALUR and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK carries a market cap of $120.69B.
- Over the past year, ALUR is down 71.3% and SYK is down 15.8% - SYK leads by 55.4 points.
- SYK has hit the wire 7 times in the past 4 weeks while ALUR has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 4 for ALUR).
- Company
- Allurion Technologies Inc.
- Stryker Corporation
- Price
- $0.68-5.00%
- $314.82-0.13%
- Market cap
- -
- $120.69B
- 1M return
- +0.00%
- -4.13%
- 1Y return
- -71.26%
- -15.83%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 4
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest ALUR
- SEC Form 10-K filed by Allurion Technologies Inc.
- Allurion Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Allurion Technologies Inc.
- SEC Form 8-K filed by Allurion Technologies Inc.
- Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
- Allurion Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
- Allurion Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Allurion Receives U.S. FDA Approval
- Gibbons Brendan M. decreased direct ownership by 15% to 10,408 units (SEC Form 5)
Latest SYK
- Stryker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Stryker reports first quarter 2026 operating results
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation